5-ethyl-2-[(1-pyrimidin-2-ylpiperidin-4-ylidene)amino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione | 944990-93-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮
• 英文名称: 5-ethyl-2-[(1-pyrimidin-2-ylpiperidin-4-ylidene)amino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione
• CAS: 944990-93-6
• 化学式: C₁₈H₁₈N₆O₄
• 分子量: 382.379
• InChiKey: AGEACPZVISGYNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  118
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
  申请人：Palani Anandan

  公开号：US20070173495A1

  公开（公告）日：2007-07-26

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.

  具有通式(I)的化合物，或其药用可接受的盐、溶剂合物、酯或互变异构体，可用于治疗代谢综合征和血脂异常等疾病、疾病或症状。
• COMBINATION THERAPIES COMPRISING PAR1 ANTAGONISTS WITH NAR AGONISTS
  申请人：Perelman Michael Sidney

  公开号：US20110065676A1

  公开（公告）日：2011-03-17

  The present invention is directed to a pharmaceutical composition comprising an effective amount of at least one PAR1 antagonist, at least one NAR agonist, optionally, an effective amount of at least one cardiovascular agent, and, optionally, a pharmaceutically acceptable carrier. The present invention also provides for the use of theses pharmaceutical compositions to treat various diseases associated with thrombosis.
• US7763623B2
  申请人：——

  公开号：US7763623B2

  公开（公告）日：2010-07-27
• [EN] HETEROCYCLES AS NICOTINIC ACID RECEPTOR AGONISTS FOR THE TREATMENT OF DYYSLIPIDEMIA<br/>[FR] HETEROCYCLES EN TANT QU'AGONISTES DU RECEPTEUR DE L'ACIDE NICOTINIQUE DESTINES AU TRAITEMENT DES DYSLIPIDEMIES
  申请人：SCHERING CORPOORATION

  公开号：WO2007087204A2

  公开（公告）日：2007-08-02

  [EN] A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.
  [FR] L'invention concerne un composé présentant une structure générale répondant à la formule (I) : ou un tautomère, un ester, un solvate ou un sel pharmaceutiquement acceptable celui-ci, utiles dans le traitement de pathologies, troubles ou états tels que le syndrome métabolique ou une dyslipidémie.